For Q4 2025, PacBio generated total revenue of 44645000, up year-over-year, with GAAP net loss of 40371000 and gross profit of 16566000. Non-GAAP gross margin improved to 40% compared to 31% in the prior year quarter.

PacBio demonstrated a strong performance in Q2 2025, achieving revenue growth both sequentially and year-over-year, reaching $39.8 million. The company significantly reduced its GAAP net loss to $41.9 million from $173.3 million in the prior year, and improved its non-GAAP net loss to $40.0 million. This positive trend was supported by disciplined cost management and increased adoption of its HiFi sequencing platforms.

PacBio reported a decrease in total revenue compared to the prior year, primarily driven by lower instrument revenue. However, consumable revenue and service and other revenue saw increases. GAAP net loss significantly widened due to substantial restructuring charges, while non-GAAP net loss slightly improved. The company initiated a restructuring plan to reduce operating expenses and focus on its long-read business.

PacBio's fourth quarter 2024 results showed a revenue of $39.2 million, a 33% decrease year-over-year. Despite this, the company reported a net income of $3.6 million, a significant improvement from a net loss of $82.0 million in the prior-year period, primarily due to a $154.4 million gain on debt restructuring. Operating expenses increased substantially due to preliminary non-cash impairment charges.

PacBio reported a net loss of $60.7 million for Q3 2024, compared to a net loss of $66.9 million for Q3 2023. The company saw positive signs, including sequential growth in consumables and continued Revio adoption, and is committed to being cash flow positive exiting 2026.

Pacific Biosciences reported a revenue increase of 19% year-over-year, driven by growth in sequencing revenue. The company highlighted the strong performance of its Revio system and advancements in its chemistry, contributing to improved data quality and throughput. While operating expenses remain significant, the company is focused on driving further adoption of its platforms and expanding its market presence.

Pacific Biosciences reported Q4 2023 revenue of $73.2 million, exceeding expectations and representing a 95% increase year-over-year. The company saw growth in instrument revenue and consumables revenue. Continued progress was made on increasing the installed base of Revio systems and improving sequencing economics.

Pacific Biosciences reported revenue of $47.6 million for Q3 2023, driven by growth in instrument revenue and sequencing revenue. The company continues to focus on expanding its customer base and driving adoption of its Revio system.

Pacific Biosciences reported strong Q2 2023 results, with revenue exceeding expectations. Instrument placements increased, and the company made progress on key strategic initiatives. The company is focused on driving further growth and innovation in long-read sequencing.

Pacific Biosciences' Q1 2023 revenue reached $38.7 million, surpassing expectations, but the company experienced a net loss, resulting in negative EPS. Instrument revenue grew, while consumables revenue declined slightly. The company highlighted progress in its product development and market expansion efforts.

Pacific Biosciences reported a revenue increase in Q4 2022, driven by higher instrument revenue and consumable sales. The company saw progress in expanding its install base and improving sequencing economics. However, net losses persisted, and operating expenses remained significant.

Pacific Biosciences reported revenue of $33.8 million for Q3 2022, a 60% increase compared to Q3 2021. The company's results were driven by growth in instrument revenue and consumables revenue. The company provided a positive outlook for the rest of the year.

Pacific Biosciences reported Q2 2022 financial results, highlighting revenue growth driven by strong instrument and consumable sales. However, the company experienced a net loss due to increased operating expenses related to investments in growth initiatives.

Pacific Biosciences reported a strong first quarter in 2022, marked by significant revenue growth driven by increased instrument sales. The company continues to focus on expanding its product portfolio and market reach.

Pacific Biosciences reported revenue of $30.5 million for Q2 2021, a 107% increase year-over-year. The company's performance was driven by increased instrument revenue and consumables revenue. The company is increasing full year revenue guidance to 112-118 million.

Pacific Biosciences reported a strong start to 2021 with significant revenue growth driven by instrument sales and increased consumables revenue. The company continues to advance its Sequel IIe system and expand its customer base.

Pacific Biosciences reported increased revenue for Q3 2020, driven by growth in instrument and consumables revenue. The company also made progress in key strategic areas, including the development of new products and expansion of its commercial operations.

Pacific Biosciences reported a strong Q2 2020 with increased revenue driven by higher instrument sales. Despite the challenges posed by the COVID-19 pandemic, the company saw growth in its sequencing platform business and progress in its strategic initiatives.